Lyfebulb and Helsinn Announce Finalists for the 2019 Innovation Summit in Oncology

Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology  

GlobeNewswire – New York, NY – February 27, 2019

  • The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using therapeutics, diagnostics, medical devices or healthcare IT tools 

MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, FEBRUARY 27 2019:  

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announce the names of the ten Patient Entrepreneurs chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Awards in Oncology. 

The following inspirational finalists will compete at the Lyfebulb-Helsinn Innovation Summit, on March 18 and 19, 2019, for two $25,000 grants: 

  • Karl Blohm, PhD of SafeHeal SAS 
  • Matt De Silva of Notable Labs 
  • Carlos Garcia of Welwaze Medical Inc. 
  • Philippe Halfon MD, PhD, PharmD of Genoscience Pharma 
  • David Hysong of Shepherd Therapeutics 
  • Pierluigi Paracchi of Genenta Science 
  • Florence Séjourné of Da Volterra  
  • Mihir Shah of UE LifeSciences Inc. 
  • Ira Spector, PhD of SFA Therapeutics Inc. 
  • Maria Zannes of bioAffinity Technologies  

The Awards will recognize outstanding Patient Entrepreneurs building groundbreaking companies to advance the prevention, diagnosis, management or care of cancer patients. The finalists represent companies that have been founded by cancer patients, cancer survivors or those with loved ones affected by cancer. A “pitch session” will be held at the summit, where a jury of experts will select the ultimate winners. 

“At Lyfebulb, we believe individuals living with a chronic disease have not only unique insights, but also solutions to address needs they identify in their daily lives. We thank and salute each and every Patient Entrepreneur who applied to our Challenge, and we look forward to the highly collaborative two days we will spend with our teams, jury and finalists, who each bring their unique strategy to reducing the burden of living with cancer, said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. 

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, added, So many of us are affected by cancer, and bringing new and advanced solutions to the marketplace is at the heart of what the Helsinn Group does. Helsinn and the Helsinn Investment Fund are  committed to positively impacting the patient community by mentoring, partnering, investing in or connecting these innovators as they pursue their entrepreneurial journey and we are delighted to be working with Lyfebulb on this summit and awards for a second year. 

About Lyfebulb 

Lyfebulb is a chronic diseasefocused, patient empowerment platform that connects patients, industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease and multiple sclerosis. 

See www.lyfebulb.com, Facebook, Twitter, Instagram, Lyfebulb LinkedIn, and Karin Hehenberger LinkedIn.  

About Helsinn International Services sarl 

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.   

 About Helsinn Investment Fund S.A., SICAR 

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients 

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.  

For more information, visit www.helsinninvestmentfund.com 

About  the  Helsinn  Group 

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally. 

To learn more about Helsinn Group please visit  www.helsinn.com 

For  more  information: 
Helsinn  Group  Media  Contact 
Paola  Bonvicini 
Group Head  of  Communication 
Lugano,  Switzerland 
Tel: +41 (0) 91 985 21 21 
Info-hhc@helsinn.com 
For more information, please follow us on Twitter, LinkedIn  and  Vimeo

Press Contact for Lyfebulb 
Karin Hehenberger, MD, PhD 
CEO & Founder, Lyfebulb,  
Phone: + 00 1 917-575-0210  
Email: karin@lyfebulb.com 
HELS-US-0031 

Havas Health & You and Lyfebulb join forces to improve the quality of life for people living with chronic diseases

Havas Health & You has announced a strategic partnership Lyfebulb that will provide a unique, differentiated means of putting the voice and needs of the patient at the center of everything Havas Health & You does for its clients

NEW YORK (PRWEB) MARCH 06, 2018

Havas Health & You, a global leader in health-and-wellness communications, announced today a strategic partnership with Lyfebulb, a patient empowerment platform that promotes a healthy, take-charge lifestyle for those affected by chronic disease. The mission of Havas Health & You is to support its clients in promoting healthy-living decisions across the entire health ecosystem.

“The Havas Health & You and Lyfebulb partnership further strengthens our shared commitment to creating meaningful connections that inspire healthy living,” said Dennis Urbaniak, chief digital officer of Havas Health & You. “By leveraging Lyfebulb’s successful track record of delivering innovative solutions for some of the most complex chronic conditions, we are demonstrating our focus on real-life results that matter.”

Lyfebulb connects patients, industry, and investors to support user-driven innovation. It has built communities of patients with chronic diseases and supported leaders in these communities through its Patient Ambassador and Patient Entrepreneur programs. By bringing Lyfebulb’s community into the Havas Health & You network offering, this partnership will provide a unique, differentiated means of putting the voice and needs of the patient at the center of everything Havas Health & You does for its clients.

“Our goal is to reduce the burden of disease in patients by bringing user-driven innovation at a large scale,” said Karin Hehenberger, M.D., Ph.D., the CEO, and founder of Lyfebulb. “Together with Havas Health & You and its broad network of clients, we will accelerate our ability to bring more comprehensive, patient-focused solutions to the marketplace.”

Presenting the full picture of any disease, from patient insights to their solutions, is a key differentiator for Havas Health & You in this new partnership. The relationships that Havas Health & You have with multinational healthcare companies, in turn, will enhance Lyfebulb’s ability to execute upon its mission to reduce disease burden for people with chronic disease.

# # #

About Havas Health & You
Havas Health & You join together the agencies and companies of Havas Health with the consumer health-and-wellness marketing communications practices across Havas companies around the world. The broadened entity and new name reflect the group’s future-forward positioning and expanded capability. Havas Health & You have built out best-in-class disciplines and integrated the many products and services the Havas agencies and companies offer across the health and wellness continuum, from Rx and OTC to health solutions.

About Lyfebulb
Lyfebulb is a chronic-disease focused patient empowerment platform that connects patients, industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, and other autoimmune diseases.

So long, farewell, J&J won’t likely miss you…

goodbye

Earlier this month, J&J announced that the 32-year veteran of the company and the face of its device business — Gary Pruden — will step down on June 1 and retire.

Interestingly, the press release announcing the replacement of Pruden did not contain the usual accolades from higher-up executives — in this case, it would likely be chairman and CEO Alex Gorsky— to recognize and thank a long-time employee. [A news report on Pruden’s departure had a statement from the company praising Pruden’s for his efforts that led to J&J’s collaboration with Google and the creation of Verb Surgical, but that was statement was nowhere in the news release ].

Instead, the company’s release almost entirely focused on his replacement —Sandra Peterson.

“Since joining the company more than four years ago, Sandi has been a valuable partner and has played a critical role in positioning Johnson & Johnson to thrive in a rapidly changing environment,” Gorsky said in the news release. “Under Sandi’s leadership, our Consumer and Consumer Medical Device businesses have improved significantly, and the quality and efficiency of our operating infrastructure have been notably strengthened. Sandi has a proven track record and brings broad-based experience and a strategic, global perspective to our Hospital Medical Device business.”

A J&J spokeswoman confirmed that to be the only news release informing the public of the leadership change in the devices business.

Pruden joined…

Patient Entrepreneur Brianna Wolin of Find Your Ditto Selected as the First Recipient of the Lyfebulb-Novo Nordisk Innovation Award

Innovation Award Recognizes One Patient Entrepreneur for Her Innovative Idea for Management of Diabetes Using Consumer, Medical Devices, or Healthcare Information Technologies

NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Find Your Ditto, Brianna Wolin was named recipient of the inaugural Lyfebulb-Novo Nordisk Innovation Award for her work in addressing the management of diabetes. Brianna was selected from a grouping of ten finalists after dozens of Award submissions were received from 15 countries. The selection was made by a panel of judges consisting of international representatives of the diabetes patient community.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cad5bf80-ac92-4973-9ba5-3d147b14a7f3.

“To be recognized by an innovative organization such as Lyfebulb and Novo Nordisk, a global pharmaceutical leader in diabetes care, is a true honor and an affirmation that our work to helping change the landscape surrounding isolation and depression in chronic illness communities is fully worthwhile,” said Brianna Wolin. “I’m so proud to have our mission – creating a world where no person living with a chronic illness ever has to feel alone – is highlighted by this award.”

The Lyfebulb-Novo Nordisk Innovation Award spotlights one outstanding patient entrepreneur’s innovative efforts and ideas to better manage chronic disease via consumer products, medical devices, or healthcare information technology.

Brianna Wolin was selected from a distinguished grouping of patient entrepreneur finalists that included:

Shilo Ben-Zeev, Smartzyme, Israel;
Jeff Dachis, OneDrop, USA;
Shantanu Gaur, MD, Allurion, USA;
Matt Loper, Wellth, USA;
Charles O’Connell, FitScript, USA;
Scott Smith, Socrates, USA;
Anna Sjoberg, Anna PS, Sweden;
John Sjolund, Patients Pending Ltd, UK;
David Weingard, Fit4D, USA;
Brianna Wolin, Find Your Ditto, USA.

All finalists attended the Innovation Summit held December 6-7, 2016 hosted by Novo Nordisk in Copenhagen, Denmark. The Summit was designed to provide an opportunity for visibility and recognition in this highly competitive arena as well as professional discussion and inspiration for developing ideas further.

“With the global interest in and success of this first Award and event, we are excited about the future for the Innovation Award to grow and for Lyfebulb and Novo Nordisk to expand and strengthen our relationship,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Clearly, this effort demonstrates that patient entrepreneurs play a key role in helping people living with chronic disease. At Lyfebulb, we will continue to uncover and give voice to patient entrepreneurs who must be a part of the solution to chronic disease.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl added, “While patient-centered companies such as Novo Nordisk will continue to play an important role in bringing innovative solutions for people living with diabetes, this competition proves that passionate patient entrepreneurs are making a real difference to advance the management and care of a chronic condition such as diabetes.”

More information on the Innovation Award, the winner, the sponsors and Summit, as well as each of the finalists and selection process, can be found on the Lyfebulb Website.

About Brianna Wolin
Brianna Wolin is a passionate entrepreneur, biomedical engineer and food blogger.
Find Your Ditto, FYD, which began as a student project during her time at the University of Michigan, has earned Brianna several awards at the University as well as recognition by SPARK Ann Arbor, including a fully-funded entrepreneurial bootcamp experience and a commitment to continued guidance. Brianna has lived with Type 1 Diabetes and Celiac Disease the majority of her life. Her food blog, A Different Survival Guide, grew out of her need to cook all of her own low carb, gluten free meals unavailable in campus dining halls.
Brianna is the Chief Executive Officer of Find Your Ditto, responsible for engagement with universities and healthcare systems, marketing, legal matters, and company finances.

About Lyfebulb
Lyfebulb is an organization focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW.
See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.comFacebook, Twitter, LinkedIn, YouTube.

Press Contact for Lyfebulb: 
Shepard Doniger
BDCG, Inc.
561-637-5750
sdoniger@bdcginc.com

Holiday Gift Guide for Those Living With Diabetes Now Available

Lyfebulb brings healthier lifestyle curated gifts to shoppers this holiday season

NEW YORK, Dec. 19, 2016 (GLOBE NEWSWIRE) — Lyfebulb, an organization focused on bringing innovative products and solutions to market for those living with chronic disease and creator of the global Lyfebulb-Novo Nordisk Innovation Award, today announced the availability of its 2016 Online Holiday Gift Guide. The Holiday Gift Guide is a curated selection of the best online products for those living with diabetes and those who want to lead a healthier lifestyle in general. Many of the items were developed by “patient entrepreneurs,” who themselves live with diabetes. This concept was coined by Lyfebulb describing those who have been diagnosed with a chronic disease, or are close to someone who has, and have used this experience to create an entrepreneurial enterprise aimed at solving one or more problems their experience with chronic illness has highlighted.

We have also curated special gifts in a wide range of prices and choices for Women and Men by talented designers we admire, available at http://lyfebulb.com/2016/12/15/karins-2016-holiday-gift-guide/ for women and at http://lyfebulb.com/2016/12/16/karins-2016-holiday-gift-guide-2/ for men.

“The holiday season is here and we all love indulging our friends and family with gifts that bring joy and pleasure, but can also provide function and true benefits for those with diabetes! Our specially curated Gift Guide includes some of the most innovative yet fabulous diabetes gifts on the market!” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb.

The Diabetes Gift Guide includes a wide variety of better-for-you lifestyle and health related items ranging from the limited edition Happy Socks created by two Russian artist brothers, to the FitBit fitness tracker. The Guide also includes items such as the Sugar Sucks Sloppy Joe Sweat Shirt, and the Type One Type Happy Mug, fractions of some of these items will be donated to type 1 diabetes research.

The Women’s Gift Guide features special designer selections featuring a variety of brands ranging from such Diptyque holiday candles, an Isabel Marant sweater and a vintage Hermès bag. The Men’s guide includes items such as a Lionel Messi Barcelona Home Soccer Jersey, Orrefors tumblers, Incotex trousers, and a vintage Rolex Daytona Stainless Steel Watch.

More information about the Gift Guides, the Innovation Award, and Lyfebulb can be found on the Lyfebulb Website.

About Lyfebulb

Lyfebulb is an organization focused on bringing innovative products and solutions focused on chronic disease to market. Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

Press Contact for Lyfebulb:
Shepard Doniger
BDCG, Inc.
561-637-5750
sdoniger@bdcginc.com

Interests - Select all that apply